Health Condition 1: null- Dyslipidemia
Conditions
Interventions
Intervention1: Statin: Patients taking any drug belonging to the statin group of medicines in any dose and for any duration attending the Medicine OPD were enrolled for the study. Patients fulfilling
Sponsors
Director
Eligibility
Inclusion criteria
Inclusion criteria: INCLUSION CRITERIA FOR STATIN GROUP: 1.Patients on statin therapy with any dose and duration. 2.Age >= 18 years INCLUSION CRITERIA FOR NORMAL HEALTHY VOLUNTEERS: 1.Age >= 18 years 2.Willing to give informed consent
Exclusion criteria
Exclusion criteria: EXCLUSION CRITERIA FOR STATIN GROUP: 1.Patients with diagnosed myopathy before the start of statin therapy or other cause of myopathy 2.Patients with co-existing diabetes or other diagnosed causes of peripheral neuropathy (diabetes, renal insufficiency, use of alcohol, hypothyroidism, cancer, AIDS, connective tissue disorder, heavy metal intoxication, cobalamine and folate deficiency). 3.Patients with reported hearing loss (conductive or sensorineural) before the start of statin therapy 4.Patients who have contraindications for NCT (Pacemakers). 5.Patients taking the following drugs: chemotherapy, gold, phenytoin, amiodarone, isoniazid, ethambutol, metronidazole, nitrofurantoin, chloramphenicol, griseofulvin, disulfiram, dapsone, cimetidine, colchicine, hydralazine, pyridoxine, thalidomide. EXCLUSION CRITERIA FOR NORMAL HEALTHY VOLUNTEERS: 1.Diabetes 2.Muscular Dystrophies 3.Parkinsonâ??s Disease 4.Patients taking statins, antidiabetic drugs, anti-depressants, chemotherapeutic drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary Outcome: 1.Co-enzyme Q10 levels in patients on statin therapyTimepoint: Primary Outcome: 1.Co-enzyme Q10 levels in patients on statin therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Comparison of serum CoQ10, serum HMG CoA reductase and serum CK-MM levels in patients having statin induced muscular adverse effects with those not having adverse effects.Timepoint: 1;2. Correlation of serum HMG CoA reductase levels with serum CoQ10 levels in patients having muscular adverse effects.Timepoint: 1;3. Comparison and correlation of serum CoQ10 and serum HMG CoA reductase levels in patients having statin induced neurological adverse effects with those not having adverse effects.Timepoint: 1 | — |
Countries
India
Contacts
Public ContactDr Neha Gurha
Lady Hardinge Medical College
Outcome results
None listed